SCHEMBL973321

SCHEMBL973321

Brc1ccc(-c2cn3cc(-c4ccccc4)cc(-c4ccccc4)c3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 7/20 0.54
ALDH1A2 O94788 3/20 0.54
ADORA1 P30542 3/20 0.50
ALDH1A1 P00352 6/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
KDM4E B2RXH2 3/20 0.49
POLB P06746 2/20 0.49
ADORA2A P29274 2/20 0.49
DHODH Q02127 1/20 0.45
SLC2A1 P11166 1/20 0.44
MAPT P10636 4/20 0.44
MAPK1 P28482 2/20 0.44
APP P05067 1/20 0.44
MEN1 O00255 1/20 0.44
APEX1 P27695 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367425 1.00 ALDH1A3 (0.54) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367558 1.00 ALDH1A3 (0.54) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367423 0.94 ALDH1A3 (0.61) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367607 0.91 ALDH1A3 (0.63) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367546 0.88 ALDH1A3 (0.50) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367486 0.87 ALDH1A3 (0.52) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367506 0.87 MAPT (0.51) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367465 0.87 ALDH1A3 (0.49) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367480 0.86 ALDH1A3 (0.54) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1
SCHEMBL31367501 0.86 ALDH1A3 (0.54) ALDH1A3ALDH1A2ADORA1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed
US-7867629-B2 Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A3 8/4885ALDH1A2 4/4885ADORA1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.